Yiping Zhang
Current Organizations / Institutes
The organizations/institutes from the scholar's latest article
Research Subjects
Yiping Zhang has a total of 23 co-authors. Here are the top co-authors by number of shared publications:
Zhengbo Song
Department of Chemotherapy, Zhejiang Cancer Hospital, Hangzhou, China ; Key Laboratory Diagnosis and Treatment Technology on Thoracic Oncology, Zhejiang Province, Hangzhou, China
9 shared publicationsLan Shao
Department of Chemotherapy, Zhejiang Cancer Hospital, and Key Laboratory Diagnosis and Treatment Technology on Thoracic Oncology, Zhejiang province, Hangzhou, People's Republic of China
4 shared publications- Zhengbo Song
Department of Clinical Trial, Zhejiang Cancer Hospital, No. 1 East Banshan Road, Gongshu District, Hangzhou, Zhejiang 310022, China
4 shared publications Baochai Lin
Department of Chemotherapy, Zhejiang Cancer Hospital, and Key Laboratory Diagnosis and Treatment Technology on Thoracic Oncology, Zhejiang province, Hangzhou, People's Republic of China
3 shared publicationsBeibei Zhang
Department of Chemotherapy, Zhejiang Cancer Hospital Hangzhou, China; Key Laboratory Diagnosis and Treatment Technology on Thoracic Oncology Hangzhou, China
3 shared publicationsChunxiao He
Department of Chemotherapy, Zhejiang Cancer Hospital Hangzhou, China; Key Laboratory Diagnosis and Treatment Technology on Thoracic Oncology Hangzhou, China
3 shared publications
Latest Publications
- Open Access
- 1 January 2015
- Published by Termedia Sp. z.o.o. in Archives of Medical Science
- Vol. 1 (1) , 164-168
Efficacy of gefitinib or erlotinib in patients with squamous cell lung cancer
Introduction : The aim of this study was to evaluate the feasibility of epidermal growth factor receptor-tyrosine kinase inhibitor (EGFR-TKI) and EGFR mutation frequency in advanced squamous cell lung cancer based on the data from our hospital. Material and methods: The clinical data of 102...
- 1 January 2015
- Published by Termedia Sp. z.o.o. in Archives of Medical Science
- Vol. 1 (1) , 164-168
Open AccessEfficacy of gefitinib or erlotinib in patients with squamous cell lung cancer
Introduction : The aim of this study was to evaluate the feasibility of epidermal growth factor receptor-tyrosine kinase inhibitor (EGFR-TKI) and EGFR mutation frequency in advanced squamous cell lung cancer based on the data from our hospital. Material and methods: The clinical data of 102...
- Open Access
- 20 September 2014
- Published by Springer Nature in World Journal of Surgical Oncology
- Vol. 12 (1) , 291
Treatment and prognosis of type B2 thymoma
Because of the rarity of thymoma, no randomized trials have prospectively detected the prognosis and optimal treatment for type B2 thymoma. The aim of this study is to investigate the treatment and prognosis for patients with type B2 thymoma. We retrospectively evaluated the outcome of 42 patients with type B2 thymoma who were treated between 1995 and 2010 in Zhejiang Cancer Hospital. Survival curves were plotted using the Kaplan–Meier method. The Cox proportional hazard model was used for multivariate analysis. The current study included 42 patients. The 5-year disease-free survival and overall survival rates were 62.8% and 84.9%, respectively. There were significant differences in disease-free survival and overall survival among different Masaoka stages (both P < 0.001). Univariate and multivariate analysis revealed that Masaoka stage was associated with disease-free survival and overall survival (P = 0.00 and 0.001, respectively). Our results indicate that Masaoka stage affects disease-free survival and overall survival of patients with type B2 thymoma.
- 20 September 2014
- Published by Springer Nature in World Journal of Surgical Oncology
- Vol. 12 (1) , 291
Open AccessTreatment and prognosis of type B2 thymoma
Because of the rarity of thymoma, no randomized trials have prospectively detected the prognosis and optimal treatment for type B2 thymoma. The aim of this study is to investigate the treatment and prognosis for patients with type B2 thymoma. We retrospectively evaluated the outcome of 42 patients with type B2 thymoma who were treated between 1995 and 2010 in Zhejiang Cancer Hospital. Survival curves were plotted using the Kaplan–Meier method. The Cox proportional hazard model was used for multivariate analysis. The current study included 42 patients. The 5-year disease-free survival and overall survival rates were 62.8% and 84.9%, respectively. There were significant differences in disease-free survival and overall survival among different Masaoka stages (both P < 0.001). Univariate and multivariate analysis revealed that Masaoka stage was associated with disease-free survival and overall survival (P = 0.00 and 0.001, respectively). Our results indicate that Masaoka stage affects disease-free survival and overall survival of patients with type B2 thymoma.
- Open Access
- 1 September 2014
- Published by Elsevier in Journal of Thoracic Oncology
- Vol. 9 (9) , e67-e69
Effective Treatment with Icotinib in Primary Adenoid Cystic Carcinoma of the Lung with Liver Metastasis
- 1 September 2014
- Published by Elsevier in Journal of Thoracic Oncology
- Vol. 9 (9) , e67-e69
Open AccessEffective Treatment with Icotinib in Primary Adenoid Cystic Carcinoma of the Lung with Liver Metastasis
- Open Access
- 26 May 2014
- Published by Springer Nature in World Journal of Surgical Oncology
- Vol. 12 (1) , 165
Renal metastasis after esophagectomy of esophageal squamous cell carcinoma: a case report and literature review
Solitary metastatic renal tumors are rarely encountered. We report the case of a 63-year-old man who developed a solitary renal metastasis after undergoing an esophagectomy for esophageal squamous cell carcinoma and subsequent nephrectomy of the right kidney.
- 26 May 2014
- Published by Springer Nature in World Journal of Surgical Oncology
- Vol. 12 (1) , 165
Open AccessRenal metastasis after esophagectomy of esophageal squamous cell carcinoma: a case report and literature review
Solitary metastatic renal tumors are rarely encountered. We report the case of a 63-year-old man who developed a solitary renal metastasis after undergoing an esophagectomy for esophageal squamous cell carcinoma and subsequent nephrectomy of the right kidney.
- 1 April 2014
- Published by Elsevier in Journal of Clinical Neuroscience
- Vol. 21 (4) , 591-595
Gefitinib and erlotinib for non-small cell lung cancer patients who fail to respond to radiotherapy for brain metastases
- 1 April 2014
- Published by Elsevier in Journal of Clinical Neuroscience
- Vol. 21 (4) , 591-595
Gefitinib and erlotinib for non-small cell lung cancer patients who fail to respond to radiotherapy for brain metastases
- 3 March 2014
- Published by Wiley in Thoracic Cancer
- Vol. 5 (2) , 169-173
Docetaxel‐based chemotherapy as second‐line regimen for advanced thymic carcinoma
Thymic carcinoma is an uncommon neoplasm. The efficacy of second-line treatment with docetaxel in advanced thymic carcinoma has not been well studied. Therefore, we conducted a review of the efficacy of docetaxel-based chemotherapy as a second-line regimen for advanced thymic carcinoma. Fifteen patients with advanced thymic carcinoma who received second-line chemotherapy with docetaxel singlet or docetaxel/platinum combination chemotherapy regimens were retrospectively reviewed. There were 11 males and four females, with a median age of 53 years. Squamous cell carcinoma was most common (n = 10), followed by undifferentiated carcinoma (n = 4), and small cell carcinoma (n = 1). Eight patients received docetaxel/platinum combination chemotherapy and seven docetaxel mono-therapy. Four patients showed partial responses, representing a response rate of 26.7%. The median progression-free survival and overall survival in the 15 patients were 4.0 (2.8-5.2) and 22.0 (14.6-29.4) months, respectively. There was no difference in progression-free survival between the docetaxel singlet or docetaxel/platinum combination chemotherapy (3.5 months vs. 4.0 months, P = 0.889). A docetaxel-based regimen could be a potential therapeutic option as a second-line chemotherapy for advanced thymic carcinoma.
- 3 March 2014
- Published by Wiley in Thoracic Cancer
- Vol. 5 (2) , 169-173
Docetaxel‐based chemotherapy as second‐line regimen for advanced thymic carcinoma
Thymic carcinoma is an uncommon neoplasm. The efficacy of second-line treatment with docetaxel in advanced thymic carcinoma has not been well studied. Therefore, we conducted a review of the efficacy of docetaxel-based chemotherapy as a second-line regimen for advanced thymic carcinoma. Fifteen patients with advanced thymic carcinoma who received second-line chemotherapy with docetaxel singlet or docetaxel/platinum combination chemotherapy regimens were retrospectively reviewed. There were 11 males and four females, with a median age of 53 years. Squamous cell carcinoma was most common (n = 10), followed by undifferentiated carcinoma (n = 4), and small cell carcinoma (n = 1). Eight patients received docetaxel/platinum combination chemotherapy and seven docetaxel mono-therapy. Four patients showed partial responses, representing a response rate of 26.7%. The median progression-free survival and overall survival in the 15 patients were 4.0 (2.8-5.2) and 22.0 (14.6-29.4) months, respectively. There was no difference in progression-free survival between the docetaxel singlet or docetaxel/platinum combination chemotherapy (3.5 months vs. 4.0 months, P = 0.889). A docetaxel-based regimen could be a potential therapeutic option as a second-line chemotherapy for advanced thymic carcinoma.
- 1 January 2014
- Published by Elsevier in World Neurosurgery
- Vol. 81 (1) , 131-135
Brain Metastases from Esophageal Cancer: Clinical Review of 26 Cases
- 1 January 2014
- Published by Elsevier in World Neurosurgery
- Vol. 81 (1) , 131-135
Brain Metastases from Esophageal Cancer: Clinical Review of 26 Cases
- 4 December 2013
- Published by Springer Nature in Journal of Cancer Research and Clinical Oncology
- Vol. 140 (2) , 349-352
Adjuvant therapy in stage II thymic carcinoma
Purpose The aim of this study is to investigate the impact of chemotherapy and/or radiotherapy on disease-free survival and overall survival for patients with stage II thymic carcinoma. Methods We retrospectively evaluated the outcome of 31 patients with Masaoka stage II thymic carcinoma who were treated between 1995 and 2009 in Zhejiang Cancer Hospital. Survival curves were plotted using the Kaplan–Meier method. The Cox proportional hazard model was used for multivariate analysis. Results Thirty-one patients were included in current study. The most common histological subtypes were squamous cell carcinoma (48.4 %), followed by undifferentiated carcinoma (19.4 %) and neuroendocrine tumor (19.4 %).The 5-year disease-free survival and overall survival rate was 74.6 and 89.5 %, respectively. Univariate and multivariate analysis revealed that radiotherapy and/or chemotherapy did not statistically associated with disease-free survival and overall survival. Conclusion Our result indicated that adjuvant therapy after complete resection could not impact the disease-free survival and overall survival of patients with stage II thymic carcinoma.
- 4 December 2013
- Published by Springer Nature in Journal of Cancer Research and Clinical Oncology
- Vol. 140 (2) , 349-352
Adjuvant therapy in stage II thymic carcinoma
Purpose The aim of this study is to investigate the impact of chemotherapy and/or radiotherapy on disease-free survival and overall survival for patients with stage II thymic carcinoma. Methods We retrospectively evaluated the outcome of 31 patients with Masaoka stage II thymic carcinoma who were treated between 1995 and 2009 in Zhejiang Cancer Hospital. Survival curves were plotted using the Kaplan–Meier method. The Cox proportional hazard model was used for multivariate analysis. Results Thirty-one patients were included in current study. The most common histological subtypes were squamous cell carcinoma (48.4 %), followed by undifferentiated carcinoma (19.4 %) and neuroendocrine tumor (19.4 %).The 5-year disease-free survival and overall survival rate was 74.6 and 89.5 %, respectively. Univariate and multivariate analysis revealed that radiotherapy and/or chemotherapy did not statistically associated with disease-free survival and overall survival. Conclusion Our result indicated that adjuvant therapy after complete resection could not impact the disease-free survival and overall survival of patients with stage II thymic carcinoma.
- 9 August 2013
- Published by Wiley in The Kaohsiung Journal of Medical Sciences
- Vol. 29 (12) , 662-666
Preoperative elevation of serum C‐reactive protein as an indicator of poor prognosis for early‐stage esophageal squamous cell carcinoma
Preoperative elevation of serum C‐reactive protein (CRP) is reportedly associated with poor prognosis in several types of cancer. This study investigated the role of serum CRP as a prognostic factor in early‐stage esophageal squamous cell carcinoma (ESCC). The preoperative serum CRP levels were measured in 156 newly diagnosed pT1–2N0M0 patients using an enzyme‐linked immunosorbent assay. Correlations between serum CRP levels and other clinical parameters were analyzed. Multivariate analyses were performed to find prognostic markers using Cox's proportional hazards model. CRP concentrations were within the normal range in 117 (75%) individuals, but were elevated in 39 (25%) patients. Serum CRP levels were significantly correlated with the tumor length ( p = 0.032), depth (T classification, p = 0.0157), or histologic grade ( p = 0.034). The overall 5‐year survival rates were 76.3% and 50.2% in the low‐ and high‐CRP groups, respectively ( p = 0.005). By multivariate analyses, the elevated serum CRP level was found to be an independent prognostic factor for poor survival (hazard ratio = 2.131; p = 0.007), regardless of tumor classification or other prognostic factors. In conclusion, preoperative, high serum CRP is an independent determinant of poor prognosis in early‐stage ESCC.
- 9 August 2013
- Published by Wiley in The Kaohsiung Journal of Medical Sciences
- Vol. 29 (12) , 662-666
Preoperative elevation of serum C‐reactive protein as an indicator of poor prognosis for early‐stage esophageal squamous cell carcinoma
Preoperative elevation of serum C‐reactive protein (CRP) is reportedly associated with poor prognosis in several types of cancer. This study investigated the role of serum CRP as a prognostic factor in early‐stage esophageal squamous cell carcinoma (ESCC). The preoperative serum CRP levels were measured in 156 newly diagnosed pT1–2N0M0 patients using an enzyme‐linked immunosorbent assay. Correlations between serum CRP levels and other clinical parameters were analyzed. Multivariate analyses were performed to find prognostic markers using Cox's proportional hazards model. CRP concentrations were within the normal range in 117 (75%) individuals, but were elevated in 39 (25%) patients. Serum CRP levels were significantly correlated with the tumor length ( p = 0.032), depth (T classification, p = 0.0157), or histologic grade ( p = 0.034). The overall 5‐year survival rates were 76.3% and 50.2% in the low‐ and high‐CRP groups, respectively ( p = 0.005). By multivariate analyses, the elevated serum CRP level was found to be an independent prognostic factor for poor survival (hazard ratio = 2.131; p = 0.007), regardless of tumor classification or other prognostic factors. In conclusion, preoperative, high serum CRP is an independent determinant of poor prognosis in early‐stage ESCC.
- Open Access
- 1 August 2013
- Vol. 5 (4) , 400-405
Re-administration after the failure of gefitinib or erlotinib in patients with advanced non-small cell lung cancer
Few treatment options are available for advanced non-small cell lung cancer (NSCLC) patients who have failed of gefitinib or erlotinib treatment in second/third-line treatment. The aim of this study was to investigate the efficacy of re-administration of the same TKI after failure of gefitinib or erlotinib. The clinical data of 33 patients with advanced NSCLC were retrospectively analyzed. All of the patients were given the same TKI treatment after the failure of gefitinib or erlotinib. Survival analysis was evaluated by Kaplan-Meier method. Twenty patients (60.6%) were re-administration with gefitinib as the 2nd EGFR-TKI, and thirteen patients (39.4%) received erlotinib. One patient (3.0%) showed partial response (PR), 14 (42.4%) achieved stable disease (SD), and 18 (54.5%) had progressive disease (PD). The disease control rate was 45.5% and the median progression-free survival was 1.5 months (95% CI: 0.6-2.3 months). The PFS in patients who got disease control in the prior TKI was 2.2 and 1.2 months in the progression disease cases (P=0.29), the DCR was 54.5% and 27.3% in two group, respectively (P=0.26). Re-administration of TKI seems to be a potential therapeutic option for treatment of selected advanced NSCLC patients after failure of gefitinib or erlotinib, especially for the patients with NSCLC who once responded from the prior TKI treatment.
- 1 August 2013
- Vol. 5 (4) , 400-405
Open AccessRe-administration after the failure of gefitinib or erlotinib in patients with advanced non-small cell lung cancer
Few treatment options are available for advanced non-small cell lung cancer (NSCLC) patients who have failed of gefitinib or erlotinib treatment in second/third-line treatment. The aim of this study was to investigate the efficacy of re-administration of the same TKI after failure of gefitinib or erlotinib. The clinical data of 33 patients with advanced NSCLC were retrospectively analyzed. All of the patients were given the same TKI treatment after the failure of gefitinib or erlotinib. Survival analysis was evaluated by Kaplan-Meier method. Twenty patients (60.6%) were re-administration with gefitinib as the 2nd EGFR-TKI, and thirteen patients (39.4%) received erlotinib. One patient (3.0%) showed partial response (PR), 14 (42.4%) achieved stable disease (SD), and 18 (54.5%) had progressive disease (PD). The disease control rate was 45.5% and the median progression-free survival was 1.5 months (95% CI: 0.6-2.3 months). The PFS in patients who got disease control in the prior TKI was 2.2 and 1.2 months in the progression disease cases (P=0.29), the DCR was 54.5% and 27.3% in two group, respectively (P=0.26). Re-administration of TKI seems to be a potential therapeutic option for treatment of selected advanced NSCLC patients after failure of gefitinib or erlotinib, especially for the patients with NSCLC who once responded from the prior TKI treatment.